Featured speaker: Mr Peter Homberg, Partner, #Raupach&Wollert, Germany

Currently featured is a speaker from Pharma Partnering & Investments 2012, part of a series of conferences at the 5th Annual BioPharma Asia Convention 2012, held on 19-22 March at Marina Bay Sands, Singapore. Mr Peter Homberg is partner of the law firm Raupach & Wollert-Elmendorff and head of its Frankfurt office and of Raupach's Life Sciences Practice Group. He …

Flagship Ventures financial gain a boost for biotech industy!

Good news for all new biotech startups out there! Managing partner and CEO of Flagship Ventures, Noubar Afeyan has announced that its life sciences funds, Fund IV has surpassed its $250 million goal and could reach $270 million. This announcement will be good news to biotech industry given the gloomy financial constraint that has been affecting the industry lately. Flagship …

#Burrill raises $125M to invest in #Brazil life sciences

Burrill & Co. has recently announced the completion of its $125M Burrill Brazil Fund I, which will invest in biotechnology and pharmaceuticals in Brazil. Read the full story here. Burrill has also received approval to begin investment from the necessary Brazilian authorities, meaning it can begin awarding investments in the coming weeks. According to Burrill's website, the fund will invest …

FP7 Grant to #TiGenix to fund research and clinical development of #Cx611

Announced just before the turn of the year, the European Seventh Framework Programme allocated €2.9 million to TiGenix and Cellerix to drive forward the development of Cx611 to treat rheumatoid arthritis. As part of the REGENER-AR consortium which received a total of €5.9 million funding, TiGenix CEO Eduardo Bravo commentated by saying, "we look forward to collaborating with our partners, …

Commercialise your #celltherapy and improve your #drug discovery with #stemcells

The 7th Annual World Stem Cells & Regenerative Medicine Congress (co-located with the inaugural World Gene Therapy Congress) is taking place on the 21st-23rd May 2012 at the Victoria Park Plaza in London, UK. STREAM A – Cell Therapy & Regenerative Medicine · Make sure your leading cell therapy reaches the patients by identifying a scalable and economical commercialisation strategy …

Biogen Idec’s strategy for developing the next generation cell-culture process

Biogen Idec present their strategy for developing the next generation cell-culture process.  The manufacturing of biologics using cell culture needs to address some of the fundamentals involved in its processes if it is going to realise its full potential. Dr Thomas Ryll the Senior Director of Cell Culture Development at Biogen Idec will be giving his perspective and ideas on …

Increase market growth in #cordbloodbanking

  MarketResearch.com recently added a report on cordblood to their collection of Biotechnology market reports.   The report, “Capitalizing on Opportunities in Cord Blood Industry Growth”, announced that "over the past 12 months, the cord blood banking industry has expanded through double digit growth." The growth was stimulated by new entrants in the cord blood banking industry, as well as …